Mirum Business Model Canvas
Unlock a concise Business Model Canvas to scale value, partnerships, and monetization
Unlock Mirum’s strategic blueprint with our concise Business Model Canvas — three to five sentences that reveal how Mirum creates value, scales through partnerships, and monetizes customer segments; perfect for entrepreneurs, investors, and consultants seeking actionable insights. Purchase the full, editable Canvas to access all nine blocks, financial implications, and a ready-to-use template for strategic planning.
Partnerships
CROs and CDMOs for trials and manufacturing
CROs and CDMOs shorten time-to-market and lower capital intensity by providing specialized trial operations, CMC development, scale-up, and GMP production. They de-risk tech transfer and assure supply continuity for rare disease populations, which affect an estimated 6–8% of the global population (WHO). Structured QP release and robust quality systems enable synchronized global filings across major regulators.
Academic hepatology centers and KOL networks
Leading liver disease centers enable patient identification, protocol refinement, and rapid enrollment, shortening multicenter trial timelines by up to 30%. KOLs validate endpoints and drive guideline inclusion, which correlates with higher adoption post-approval. Co-authored publications elevate clinical credibility and long-term collaborations feed pipeline insights into cholestatic pathophysiology amid a global chronic liver disease burden of ~2 million deaths/year (WHO 2024).
Patient advocacy groups and registries
Patient advocacy groups accelerate disease awareness and trial recruitment in small populations and connect study teams to patients across more than 7,000 rare diseases affecting roughly 300 million people worldwide.
Registries document natural history, provide external comparator benchmarks and generate real-world evidence increasingly used in regulatory filings following FDA/EMA RWE guidance.
They also support patient education, adherence initiatives and co-created access programs that improve equity of care and reduce barriers to treatment.
Payers, HTA bodies, and specialty pharmacy networks
Early engagement with payers and HTA bodies shapes value dossiers and outcomes contracts, and HTA alignment in 2024 clarified evidence thresholds for many rare indications; specialty pharmacies ensure appropriate dispensing, cold-chain integrity and patient support, while data-sharing agreements enable persistence and outcomes monitoring—specialty drugs now account for ~50% of US drug spend despite <3% of prescriptions.
- Early HTA engagement
- Outcomes-based contracts
- Specialty pharmacy cold-chain & support
- Data-sharing for persistence/outcomes
Diagnostic and biomarker laboratories
Partnerships with diagnostic and biomarker laboratories enable Mirum to screen eligible patients via bile acid, genetic and biomarker panels, while companion diagnostics refine targeting and quantify treatment response; lab integration reduces diagnosis-to-therapy time. Shared datasets from trials and real-world cohorts (2024 IVD market ~100B USD) strengthen mechanistic validation.
- Screening: bile acid/genetic/biomarker panels
- Companion diagnostics: target & response
- Faster diagnosis-to-therapy
- Shared datasets: mechanistic validation
Partners cut time-to-market 30%, connect 300M patients, IVD ≈ 100B USD
CROs/CDMOs cut time-to-market up to 30% and ensure GMP supply; liver centers/KOLs shorten enrollment ~30% and validate endpoints amid ~2M annual liver deaths (WHO 2024); patient groups/registries connect ~300M rare-disease patients and enable RWE; payers/HTA/specialty pharmacies shape access as specialty drugs = ~50% US drug spend (2024), diagnostics (IVD) market ≈100B USD (2024).
| Partner | Role | 2024 metric |
|---|---|---|
| CROs/CDMOs | Time-to-market, GMP supply | Up to −30% timelines |
| Liver centers/KOLs | Enrollment, endpoints | ~30% faster; 2M liver deaths/yr |
| Patients/registries | RWE, recruitment | ~300M rare-disease patients |
| Payers/HTA/Pharmacies | Access, outcomes | Specialty = ~50% US spend |
| Diagnostics | Screening, companion Dx | IVD market ≈100B USD |
What is included in the product
Detailed Word Document
A comprehensive Mirum Business Model Canvas mapping customer segments, value propositions, channels and revenue streams across the 9 classic BMC blocks, with narrative, competitive advantages and linked SWOT analysis for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
Mirum Business Model Canvas eliminates the pain of formatting and scattered notes by delivering an editable one-page snapshot of your strategy. It saves hours, improves team alignment, and makes comparing or iterating business models fast and effortless.
Activities
Clinical development in cholestatic liver diseases
Design and execution of Phase 2–4 trials span pediatric and adult cohorts for maralixibat, leveraging the FDA approval in 2021 for Alagille syndrome to accelerate registrational and lifecycle studies. Endpoint selection prioritizes clinician- and patient-reported pruritus scales, serum bile acid reductions and validated quality-of-life instruments. Global site activation and rare-disease retention tactics focus on specialist centers and patient advocacy networks, with post-marketing studies planned to support expanded indications and label claims.
Regulatory strategy and lifecycle management
Engage FDA, EMA and other agencies to secure orphan, fast track or breakthrough designations, leveraging FDA goal review times of 10 months (standard) and 6 months (priority) and EMA centralized review of ~210 days. Prepare INDs, NDAs/MAAs and formal responses to agency queries. Pursue label expansions via supplemental filings and PIPs. Maintain RMPs and continuous pharmacovigilance to sustain compliance.
Manufacturing scale-up and supply chain assurance
Tech transfer and process validation scale Mirum from clinical to dual-site GMP production to protect supply for orphan populations (US orphan threshold <200,000; WHO estimates 300 million people live with rare diseases globally). Forecasting models account for small, geographically dispersed cohorts and enable targeted batch runs. Cold-chain logistics (2–8°C or ultra-cold as required) plus serialization per EU/FDA track-and-trace rules ensure traceability. Continuous quality monitoring and real-time analytics minimize interruptions and support regulatory compliance.
Medical affairs and scientific education
Medical affairs drives MSL engagement, congress presentations and peer-reviewed publications to build credibility for Mirum (NASDAQ: MIRM), developing evidence-based HCP and payer materials and convening advisory boards to capture treatment insights and unmet needs. Real-world data generation supports uptake and reimbursement decisions.
- MSL-led HCP engagement
- Congress abstracts & publications
- Evidence materials for HCPs/payers
- Advisory boards capturing unmet needs
- RWE generation for uptake & reimbursement
Market access and patient support operations
Market access and patient support operations build value dossiers and execute ICER/HTA submissions and pricing strategy development; in 2024 firms prioritized outcomes contracting to align payment with real-world value. Prior authorization support, copay assistance and nurse navigation reduce access friction, while adherence programs improve persistence in chronic conditions and lower total cost of care.
- Value dossier & HTA alignment
- Pricing strategy & outcomes contracting
- Prior auth, copay, nurse navigation
- Adherence programs → higher persistence
Design/execution of Phase 2–4 trials across cohorts; accelerate registrational filings
Design/execution of Phase 2–4 trials across pediatric/adult cohorts; endpoints: clinician/patient pruritus scales, serum bile acids, QoL; leverage 2021 FDA approval for registrational acceleration. Regulatory: IND/NDA/MAA filings, orphan/priority designations (FDA review 6–10 months; EMA ~210 days). Manufacturing: dual-site GMP, cold-chain, serialization; supply planning for US orphan <200,000. Market access: HTA dossiers, outcomes contracting, prior auth and patient support.
| Activity | KPI | 2024 benchmark |
|---|---|---|
| Trials | Subjects/site | 5–15 rare-disease pts/site |
| Regulatory | Review time | FDA 6–10 months; EMA ~210 days |
| Manufacturing | Batch runs/year | 4–12 targeted runs |
| Market access | Outcomes contracts | Adopted by top payers in 2024 |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual Mirum Business Model Canvas you'll receive—not a mockup. After purchase you'll download this exact file, complete and editable. It comes formatted for immediate use in Word and Excel, with all sections included.
Unlock a concise Business Model Canvas to scale value, partnerships, and monetization
Unlock Mirum’s strategic blueprint with our concise Business Model Canvas — three to five sentences that reveal how Mirum creates value, scales through partnerships, and monetizes customer segments; perfect for entrepreneurs, investors, and consultants seeking actionable insights. Purchase the full, editable Canvas to access all nine blocks, financial implications, and a ready-to-use template for strategic planning.
Partnerships
CROs and CDMOs for trials and manufacturing
CROs and CDMOs shorten time-to-market and lower capital intensity by providing specialized trial operations, CMC development, scale-up, and GMP production. They de-risk tech transfer and assure supply continuity for rare disease populations, which affect an estimated 6–8% of the global population (WHO). Structured QP release and robust quality systems enable synchronized global filings across major regulators.
Academic hepatology centers and KOL networks
Leading liver disease centers enable patient identification, protocol refinement, and rapid enrollment, shortening multicenter trial timelines by up to 30%. KOLs validate endpoints and drive guideline inclusion, which correlates with higher adoption post-approval. Co-authored publications elevate clinical credibility and long-term collaborations feed pipeline insights into cholestatic pathophysiology amid a global chronic liver disease burden of ~2 million deaths/year (WHO 2024).
Patient advocacy groups and registries
Patient advocacy groups accelerate disease awareness and trial recruitment in small populations and connect study teams to patients across more than 7,000 rare diseases affecting roughly 300 million people worldwide.
Registries document natural history, provide external comparator benchmarks and generate real-world evidence increasingly used in regulatory filings following FDA/EMA RWE guidance.
They also support patient education, adherence initiatives and co-created access programs that improve equity of care and reduce barriers to treatment.
Payers, HTA bodies, and specialty pharmacy networks
Early engagement with payers and HTA bodies shapes value dossiers and outcomes contracts, and HTA alignment in 2024 clarified evidence thresholds for many rare indications; specialty pharmacies ensure appropriate dispensing, cold-chain integrity and patient support, while data-sharing agreements enable persistence and outcomes monitoring—specialty drugs now account for ~50% of US drug spend despite <3% of prescriptions.
- Early HTA engagement
- Outcomes-based contracts
- Specialty pharmacy cold-chain & support
- Data-sharing for persistence/outcomes
Diagnostic and biomarker laboratories
Partnerships with diagnostic and biomarker laboratories enable Mirum to screen eligible patients via bile acid, genetic and biomarker panels, while companion diagnostics refine targeting and quantify treatment response; lab integration reduces diagnosis-to-therapy time. Shared datasets from trials and real-world cohorts (2024 IVD market ~100B USD) strengthen mechanistic validation.
- Screening: bile acid/genetic/biomarker panels
- Companion diagnostics: target & response
- Faster diagnosis-to-therapy
- Shared datasets: mechanistic validation
Partners cut time-to-market 30%, connect 300M patients, IVD ≈ 100B USD
CROs/CDMOs cut time-to-market up to 30% and ensure GMP supply; liver centers/KOLs shorten enrollment ~30% and validate endpoints amid ~2M annual liver deaths (WHO 2024); patient groups/registries connect ~300M rare-disease patients and enable RWE; payers/HTA/specialty pharmacies shape access as specialty drugs = ~50% US drug spend (2024), diagnostics (IVD) market ≈100B USD (2024).
| Partner | Role | 2024 metric |
|---|---|---|
| CROs/CDMOs | Time-to-market, GMP supply | Up to −30% timelines |
| Liver centers/KOLs | Enrollment, endpoints | ~30% faster; 2M liver deaths/yr |
| Patients/registries | RWE, recruitment | ~300M rare-disease patients |
| Payers/HTA/Pharmacies | Access, outcomes | Specialty = ~50% US spend |
| Diagnostics | Screening, companion Dx | IVD market ≈100B USD |
What is included in the product
Detailed Word Document
A comprehensive Mirum Business Model Canvas mapping customer segments, value propositions, channels and revenue streams across the 9 classic BMC blocks, with narrative, competitive advantages and linked SWOT analysis for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
Mirum Business Model Canvas eliminates the pain of formatting and scattered notes by delivering an editable one-page snapshot of your strategy. It saves hours, improves team alignment, and makes comparing or iterating business models fast and effortless.
Activities
Clinical development in cholestatic liver diseases
Design and execution of Phase 2–4 trials span pediatric and adult cohorts for maralixibat, leveraging the FDA approval in 2021 for Alagille syndrome to accelerate registrational and lifecycle studies. Endpoint selection prioritizes clinician- and patient-reported pruritus scales, serum bile acid reductions and validated quality-of-life instruments. Global site activation and rare-disease retention tactics focus on specialist centers and patient advocacy networks, with post-marketing studies planned to support expanded indications and label claims.
Regulatory strategy and lifecycle management
Engage FDA, EMA and other agencies to secure orphan, fast track or breakthrough designations, leveraging FDA goal review times of 10 months (standard) and 6 months (priority) and EMA centralized review of ~210 days. Prepare INDs, NDAs/MAAs and formal responses to agency queries. Pursue label expansions via supplemental filings and PIPs. Maintain RMPs and continuous pharmacovigilance to sustain compliance.
Manufacturing scale-up and supply chain assurance
Tech transfer and process validation scale Mirum from clinical to dual-site GMP production to protect supply for orphan populations (US orphan threshold <200,000; WHO estimates 300 million people live with rare diseases globally). Forecasting models account for small, geographically dispersed cohorts and enable targeted batch runs. Cold-chain logistics (2–8°C or ultra-cold as required) plus serialization per EU/FDA track-and-trace rules ensure traceability. Continuous quality monitoring and real-time analytics minimize interruptions and support regulatory compliance.
Medical affairs and scientific education
Medical affairs drives MSL engagement, congress presentations and peer-reviewed publications to build credibility for Mirum (NASDAQ: MIRM), developing evidence-based HCP and payer materials and convening advisory boards to capture treatment insights and unmet needs. Real-world data generation supports uptake and reimbursement decisions.
- MSL-led HCP engagement
- Congress abstracts & publications
- Evidence materials for HCPs/payers
- Advisory boards capturing unmet needs
- RWE generation for uptake & reimbursement
Market access and patient support operations
Market access and patient support operations build value dossiers and execute ICER/HTA submissions and pricing strategy development; in 2024 firms prioritized outcomes contracting to align payment with real-world value. Prior authorization support, copay assistance and nurse navigation reduce access friction, while adherence programs improve persistence in chronic conditions and lower total cost of care.
- Value dossier & HTA alignment
- Pricing strategy & outcomes contracting
- Prior auth, copay, nurse navigation
- Adherence programs → higher persistence
Design/execution of Phase 2–4 trials across cohorts; accelerate registrational filings
Design/execution of Phase 2–4 trials across pediatric/adult cohorts; endpoints: clinician/patient pruritus scales, serum bile acids, QoL; leverage 2021 FDA approval for registrational acceleration. Regulatory: IND/NDA/MAA filings, orphan/priority designations (FDA review 6–10 months; EMA ~210 days). Manufacturing: dual-site GMP, cold-chain, serialization; supply planning for US orphan <200,000. Market access: HTA dossiers, outcomes contracting, prior auth and patient support.
| Activity | KPI | 2024 benchmark |
|---|---|---|
| Trials | Subjects/site | 5–15 rare-disease pts/site |
| Regulatory | Review time | FDA 6–10 months; EMA ~210 days |
| Manufacturing | Batch runs/year | 4–12 targeted runs |
| Market access | Outcomes contracts | Adopted by top payers in 2024 |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual Mirum Business Model Canvas you'll receive—not a mockup. After purchase you'll download this exact file, complete and editable. It comes formatted for immediate use in Word and Excel, with all sections included.
Original: $10.00
-65%$10.00
$3.50Description
Unlock a concise Business Model Canvas to scale value, partnerships, and monetization
Unlock Mirum’s strategic blueprint with our concise Business Model Canvas — three to five sentences that reveal how Mirum creates value, scales through partnerships, and monetizes customer segments; perfect for entrepreneurs, investors, and consultants seeking actionable insights. Purchase the full, editable Canvas to access all nine blocks, financial implications, and a ready-to-use template for strategic planning.
Partnerships
CROs and CDMOs for trials and manufacturing
CROs and CDMOs shorten time-to-market and lower capital intensity by providing specialized trial operations, CMC development, scale-up, and GMP production. They de-risk tech transfer and assure supply continuity for rare disease populations, which affect an estimated 6–8% of the global population (WHO). Structured QP release and robust quality systems enable synchronized global filings across major regulators.
Academic hepatology centers and KOL networks
Leading liver disease centers enable patient identification, protocol refinement, and rapid enrollment, shortening multicenter trial timelines by up to 30%. KOLs validate endpoints and drive guideline inclusion, which correlates with higher adoption post-approval. Co-authored publications elevate clinical credibility and long-term collaborations feed pipeline insights into cholestatic pathophysiology amid a global chronic liver disease burden of ~2 million deaths/year (WHO 2024).
Patient advocacy groups and registries
Patient advocacy groups accelerate disease awareness and trial recruitment in small populations and connect study teams to patients across more than 7,000 rare diseases affecting roughly 300 million people worldwide.
Registries document natural history, provide external comparator benchmarks and generate real-world evidence increasingly used in regulatory filings following FDA/EMA RWE guidance.
They also support patient education, adherence initiatives and co-created access programs that improve equity of care and reduce barriers to treatment.
Payers, HTA bodies, and specialty pharmacy networks
Early engagement with payers and HTA bodies shapes value dossiers and outcomes contracts, and HTA alignment in 2024 clarified evidence thresholds for many rare indications; specialty pharmacies ensure appropriate dispensing, cold-chain integrity and patient support, while data-sharing agreements enable persistence and outcomes monitoring—specialty drugs now account for ~50% of US drug spend despite <3% of prescriptions.
- Early HTA engagement
- Outcomes-based contracts
- Specialty pharmacy cold-chain & support
- Data-sharing for persistence/outcomes
Diagnostic and biomarker laboratories
Partnerships with diagnostic and biomarker laboratories enable Mirum to screen eligible patients via bile acid, genetic and biomarker panels, while companion diagnostics refine targeting and quantify treatment response; lab integration reduces diagnosis-to-therapy time. Shared datasets from trials and real-world cohorts (2024 IVD market ~100B USD) strengthen mechanistic validation.
- Screening: bile acid/genetic/biomarker panels
- Companion diagnostics: target & response
- Faster diagnosis-to-therapy
- Shared datasets: mechanistic validation
Partners cut time-to-market 30%, connect 300M patients, IVD ≈ 100B USD
CROs/CDMOs cut time-to-market up to 30% and ensure GMP supply; liver centers/KOLs shorten enrollment ~30% and validate endpoints amid ~2M annual liver deaths (WHO 2024); patient groups/registries connect ~300M rare-disease patients and enable RWE; payers/HTA/specialty pharmacies shape access as specialty drugs = ~50% US drug spend (2024), diagnostics (IVD) market ≈100B USD (2024).
| Partner | Role | 2024 metric |
|---|---|---|
| CROs/CDMOs | Time-to-market, GMP supply | Up to −30% timelines |
| Liver centers/KOLs | Enrollment, endpoints | ~30% faster; 2M liver deaths/yr |
| Patients/registries | RWE, recruitment | ~300M rare-disease patients |
| Payers/HTA/Pharmacies | Access, outcomes | Specialty = ~50% US spend |
| Diagnostics | Screening, companion Dx | IVD market ≈100B USD |
What is included in the product
Detailed Word Document
A comprehensive Mirum Business Model Canvas mapping customer segments, value propositions, channels and revenue streams across the 9 classic BMC blocks, with narrative, competitive advantages and linked SWOT analysis for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
Mirum Business Model Canvas eliminates the pain of formatting and scattered notes by delivering an editable one-page snapshot of your strategy. It saves hours, improves team alignment, and makes comparing or iterating business models fast and effortless.
Activities
Clinical development in cholestatic liver diseases
Design and execution of Phase 2–4 trials span pediatric and adult cohorts for maralixibat, leveraging the FDA approval in 2021 for Alagille syndrome to accelerate registrational and lifecycle studies. Endpoint selection prioritizes clinician- and patient-reported pruritus scales, serum bile acid reductions and validated quality-of-life instruments. Global site activation and rare-disease retention tactics focus on specialist centers and patient advocacy networks, with post-marketing studies planned to support expanded indications and label claims.
Regulatory strategy and lifecycle management
Engage FDA, EMA and other agencies to secure orphan, fast track or breakthrough designations, leveraging FDA goal review times of 10 months (standard) and 6 months (priority) and EMA centralized review of ~210 days. Prepare INDs, NDAs/MAAs and formal responses to agency queries. Pursue label expansions via supplemental filings and PIPs. Maintain RMPs and continuous pharmacovigilance to sustain compliance.
Manufacturing scale-up and supply chain assurance
Tech transfer and process validation scale Mirum from clinical to dual-site GMP production to protect supply for orphan populations (US orphan threshold <200,000; WHO estimates 300 million people live with rare diseases globally). Forecasting models account for small, geographically dispersed cohorts and enable targeted batch runs. Cold-chain logistics (2–8°C or ultra-cold as required) plus serialization per EU/FDA track-and-trace rules ensure traceability. Continuous quality monitoring and real-time analytics minimize interruptions and support regulatory compliance.
Medical affairs and scientific education
Medical affairs drives MSL engagement, congress presentations and peer-reviewed publications to build credibility for Mirum (NASDAQ: MIRM), developing evidence-based HCP and payer materials and convening advisory boards to capture treatment insights and unmet needs. Real-world data generation supports uptake and reimbursement decisions.
- MSL-led HCP engagement
- Congress abstracts & publications
- Evidence materials for HCPs/payers
- Advisory boards capturing unmet needs
- RWE generation for uptake & reimbursement
Market access and patient support operations
Market access and patient support operations build value dossiers and execute ICER/HTA submissions and pricing strategy development; in 2024 firms prioritized outcomes contracting to align payment with real-world value. Prior authorization support, copay assistance and nurse navigation reduce access friction, while adherence programs improve persistence in chronic conditions and lower total cost of care.
- Value dossier & HTA alignment
- Pricing strategy & outcomes contracting
- Prior auth, copay, nurse navigation
- Adherence programs → higher persistence
Design/execution of Phase 2–4 trials across cohorts; accelerate registrational filings
Design/execution of Phase 2–4 trials across pediatric/adult cohorts; endpoints: clinician/patient pruritus scales, serum bile acids, QoL; leverage 2021 FDA approval for registrational acceleration. Regulatory: IND/NDA/MAA filings, orphan/priority designations (FDA review 6–10 months; EMA ~210 days). Manufacturing: dual-site GMP, cold-chain, serialization; supply planning for US orphan <200,000. Market access: HTA dossiers, outcomes contracting, prior auth and patient support.
| Activity | KPI | 2024 benchmark |
|---|---|---|
| Trials | Subjects/site | 5–15 rare-disease pts/site |
| Regulatory | Review time | FDA 6–10 months; EMA ~210 days |
| Manufacturing | Batch runs/year | 4–12 targeted runs |
| Market access | Outcomes contracts | Adopted by top payers in 2024 |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual Mirum Business Model Canvas you'll receive—not a mockup. After purchase you'll download this exact file, complete and editable. It comes formatted for immediate use in Word and Excel, with all sections included.
